By co-opting chromatin-modifying complexes to activate cyclin-driven cell cycle programs, Olig1/2 may license neural precursor-like proliferative states in glioma stem cells—a potential vulnerability for targeted therapies (Figure 6G). Here, OLIG1 is linked to central nervous system cancer.